Literature DB >> 16913693

Medicinal chemistry of hERG optimizations: Highlights and hang-ups.

Craig Jamieson1, Elizabeth M Moir, Zoran Rankovic, Grant Wishart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16913693     DOI： 10.1021/jm060379l

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  45 in total

1.  Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.

Authors:  Luca Settimo; Krista Bellman; Ronald M A Knegtel
Journal:  Pharm Res       Date:  2013-11-19       Impact factor: 4.200

2.  Compilation and physicochemical classification analysis of a diverse hERG inhibition database.

Authors:  Remigijus Didziapetris; Kiril Lanevskij
Journal:  J Comput Aided Mol Des       Date:  2016-10-25       Impact factor: 3.686

3.  Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Authors:  Pamela A Haile; Linda N Casillas; Michael J Bury; John F Mehlmann; Robert Singhaus; Adam K Charnley; Terry V Hughes; Michael P DeMartino; Gren Z Wang; Joseph J Romano; Xiaoyang Dong; Nikolay V Plotnikov; Ami S Lakdawala; Maire A Convery; Bartholomew J Votta; David B Lipshutz; Biva M Desai; Barbara Swift; Carol A Capriotti; Scott B Berger; Mukesh K Mahajan; Michael A Reilly; Elizabeth J Rivera; Helen H Sun; Rakesh Nagilla; Carol LePage; Michael T Ouellette; Rachel D Totoritis; Brian T Donovan; Barry S Brown; Khuram W Chaudhary; Peter J Gough; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2018-09-26       Impact factor: 4.345

4.  Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.

Authors:  Renato Skerlj; Gary Bridger; Yuanxi Zhou; Elyse Bourque; Ernest McEachern; Sanjay Danthi; Jonathan Langille; Curtis Harwig; Duane Veale; Bryon Carpenter; Tuya Ba; Michael Bey; Ian Baird; Trevor Wilson; Markus Metz; Ron MacFarland; Renee Mosi; Veronique Bodart; Rebecca Wong; Simon Fricker; Dana Huskens; Dominique Schols
Journal:  ACS Med Chem Lett       Date:  2012-01-25       Impact factor: 4.345

5.  Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.

Authors:  Jérôme Molette; Julie Routier; Nada Abla; Dominique Besson; Agnes Bombrun; Reto Brun; Howard Burt; Katrin Georgi; Marcel Kaiser; Solomon Nwaka; Mathilde Muzerelle; Alexander Scheer
Journal:  ACS Med Chem Lett       Date:  2013-09-22       Impact factor: 4.345

6.  Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.

Authors:  Delia Blanco; Esther Perez-Herran; Mónica Cacho; Lluís Ballell; Julia Castro; Rubén González Del Río; José Luis Lavandera; Modesto J Remuiñán; Cindy Richards; Joaquin Rullas; María Jesús Vázquez-Muñiz; Ermias Woldu; María Cleofé Zapatero-González; Iñigo Angulo-Barturen; Alfonso Mendoza; David Barros
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

7.  Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Authors:  Michael A Brodney; Elizabeth M Beck; Christopher R Butler; Gabriela Barreiro; Eric F Johnson; David Riddell; Kevin Parris; Charles E Nolan; Ying Fan; Kevin Atchison; Cathleen Gonzales; Ashley E Robshaw; Shawn D Doran; Mark W Bundesmann; Leanne Buzon; Jason Dutra; Kevin Henegar; Erik LaChapelle; Xinjun Hou; Bruce N Rogers; Jayvardhan Pandit; Ricardo Lira; Luis Martinez-Alsina; Peter Mikochik; John C Murray; Kevin Ogilvie; Loren Price; Subas M Sakya; Aijia Yu; Yong Zhang; Brian T O'Neill
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

Review 8.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

9.  4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides.

Authors:  Marvin J Meyers; Jianguang Liu; Jing Xu; Fang Leng; Jiantong Guan; Zhijun Liu; Sarah A McNitt; Limei Qin; Linglin Dai; Hongwei Ma; Dickson Adah; Siting Zhao; Xiaofen Li; Alex J Polino; Armiyaw S Nasamu; Daniel E Goldberg; Xiaorong Liu; Yongzhi Lu; Zhengchao Tu; Xiaoping Chen; Micky D Tortorella
Journal:  J Med Chem       Date:  2019-03-22       Impact factor: 7.446

10.  Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.

Authors:  Peter Mubanga Cheuka; Nina Lawrence; Dale Taylor; Sergio Wittlin; Kelly Chibale
Journal:  Medchemcomm       Date:  2018-09-06       Impact factor: 3.597
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.